News from MS market ’07
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years >>>
<<< Despite the comparatively large MS population, the UK only accounted for 1.1% of the 7MM (major market) total in 2006. Datamonitor believes the UK has potential to be a much more profitable and attractive MS market. If treatment rates were on par with Germany, the UK market could have been worth $293m in 2006almost six times higher than the actual value.
In order to successfully position a new drug class in the market, future market players must have a clear and focused marketing strategy. With Copaxone launched in 1997 Teva has set the benchmark, and by utilizing similar tactics, future MS players can successfully position novel therapies in the market >>>
Full article – Pharmaceutical Business Review
* * * * *
Honestly, I can not catch the point of this article.
No single word about MS sufferers, MS symptoms reducing or elimination, nothing…
They speak about market, profits and possibilities (strategies) to make even money money (smart strategies). MONEY!
No single word about their drugs – what they are supposed to treat, efficiency, reliability, side effects etc.
By the way – all so-called MS drugs are experimental. Again – pharmaceutical industry makes multi-billion USD business, performing experiments on humans. More information: MS Treatment Market will Reach $11.9 Billion by 2011.
Psychology behind the scenes is shortly described in article Advantages of MS ! ? !.
However, there are lots of folks who managed to stop and/or reverse their MS symptoms.
I reversed my MS symptoms in 1997. I am on a permanent MS remission since.
One more thing – Multiple Sclerosis has the same origins as all other autoimmune diseases.
Everyone MUST choose what is best to him or her